創夢天地(01119.HK)認購Mighty Jaxx 0.89%股權 展開戰略合作
創夢天地(01119.HK)公佈,全資附屬創夢天地控股(香港)與數位化潮玩收藏品開發商Mighty Jaxx訂立股權認購協議。股權認購完成後,創夢天地控股(香港)將直接持有Mighty Jaxx 0.89%的股權。Mighty Jaxx於2015年4月在新加坡共和國註冊成立的私人有限公司,主要從事實體數位化潮玩收藏品開發。
與此同時,公司中國綜合聯屬主體深圳市創夢天地娛樂已於近日與Mighty Jaxx訂立採購及分銷協議,據此,深圳市創夢天地娛樂享有Mighty Jaxx相關產品之經銷權,有權於中國境內在該採購及分銷協議的規限下銷售Mighty Jaxx產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.